Role of Amlodipine in Reduction of CIN

Minia University

Status and phase: Not yet enrolling; Early Phase 1

Conditions: Contrast-induced Nephropathy

Treatments: Drug: Calcium channel blocker; Other: Hydration

Study type: Interventional

Funder types: Other

Identifiers

NCT07291375

Amlodipine role in CIN

Details and patient eligibility

About

The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3

Exclusion criteria

• patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

Control group

Other group

Description:

this group who undergoing iv contrast will receive hydration only

Treatment:

Other: Hydration

Amlodipine group

Other group

Description:

this group will receive hydration and amlodipine

Treatment:

Other: Hydration

Drug: Calcium channel blocker